SCHEMBL4180522

SCHEMBL4180522

CCOC(=O)CCCCS

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.59
ALDH1A1 P00352 3/20 0.49
ALOX15 P16050 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
CYP3A4 P08684 1/20 0.49
TSHR P16473 1/20 0.49
HSD17B10 Q99714 1/20 0.49
DGKA P23743 1/20 0.48
GAA P10253 2/20 0.48
MGAM O43451 1/20 0.48
SI P14410 1/20 0.48
MGAM2 Q2M2H8 1/20 0.48
NR1I2 O75469 1/20 0.47
PGR P06401 1/20 0.47
ADORA3 P0DMS8 1/20 0.47
PTGS2 P35354 1/20 0.47
PDE4D Q08499 1/20 0.47
FOLH1 Q04609 1/20 0.46
CYP4F2 P78329 1/20 0.46
CYP4A11 Q02928 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8987382 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL29132867 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL6221918 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL7075209 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL8987375 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL1593860 0.98 CYP1A2 (0.57) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL5830474 0.93
SCHEMBL11305856 0.91 CYP1A2 (0.59) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL8570508 0.88 CYP1A2 (0.73) CYP1A2ALDH1A1ALOX15TDP1CYP3A4
SCHEMBL50610 0.88 CYP1A2 (0.73) CYP1A2ALDH1A1ALOX15TDP1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388615-A9 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX, INC. (US) 2025-12-25 US disclosed
US-20250066410-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX, INC. (US) 2025-02-27 US disclosed
US-12084472-B2 Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists ARDELYX, INC. (US) 2024-09-10 US disclosed
US-20220306672-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX, INC. (US) 2022-09-29 US disclosed
EP-3390382-B1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX INC (US) 2021-12-01 EP disclosed
CN-108699028-B Substituted 4-phenylpyridines as non-systemic TGR5 agonists 阿德利克斯公司 2021-10-22 CN disclosed
US-10968246-B2 Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists ARDELYX, INC. (US) 2021-04-06 US disclosed
US-20200062795-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX, INC. (US) 2020-02-27 US disclosed
US-10392413-B2 Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists ARDELYX, INC. (US) 2019-08-27 US disclosed
EP-3390382-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS Ardelyx, Inc. (US) 2018-10-24 EP disclosed
WO-2000024719-A1 PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS ABBOTT LABORATORIES (US) 2000-05-04 WO disclosed
US-4609673-A ANTILIPEMIC AGENTS BOEHRINGER MANNHEIM GMBH (DE) 1986-09-02 US disclosed
EP-0051284-B1 NOVEL THIAPROSTAGLANDIN E1 DERIVATIVES, PROCESS FOR PRODUCTION THEREOF, AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS TEIJIN LIMITED (JP) 1985-01-09 EP disclosed
US-4466980-A Thiaprostaglandin E1 derivatives, process for production thereof, and pharmaceutical use thereof TEIJIN LIMITED (JP) 1984-08-21 US disclosed
EP-0051284-A1 Novel thiaprostaglandin E1 derivatives, process for production thereof, and pharmaceuticals containing these compounds TEIJIN LIMITED (JP) 1982-05-12 EP disclosed
US-4320070-A ION EXCHANGE RESIN CATALYST PPG INDUSTRIES, INC. (US) 1982-03-16 US disclosed
US-4273725-A Process for preparing chlorothiolformates PPG INDUSTRIES, INC. (US) 1981-06-16 US disclosed
US-4268456-A FROM A MERCAPTAN AND PHOSGENE, QUATERNARY AMMONIUM SALT CATALYST PPG INDUSTRIES, INC. (US) 1981-05-19 US disclosed
US-4175201-A Chemical synthesis UNIVERSITY OF CHICAGO (US) 1979-11-20 US disclosed
US-4018820-A Chemical synthesis THE UNIVERSITY OF CHICAGO (US) 1977-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066410-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS GPR119, GIPR, GLP1R CYP1A2 1241/4885ALDH1A1 4357/4885ALOX15 1853/4885
US-20250388615-A9 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS GPR119, GIPR, FFAR3 CYP1A2 1343/4885ALDH1A1 3776/4885ALOX15 2156/4885
US-20200062795-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS GPR119, GIPR, GLP1R CYP1A2 1241/4885ALDH1A1 4357/4885ALOX15 1853/4885
US-10968246-B2 Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists GPR119, GIPR, GLP1R CYP1A2 1241/4885ALDH1A1 4357/4885ALOX15 1853/4885
US-10392413-B2 Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists GPR119, GIPR, GLP1R CYP1A2 1241/4885ALDH1A1 4357/4885ALOX15 1853/4885
US-20220306672-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS GPR119, GIPR, GLP1R CYP1A2 1241/4885ALDH1A1 4357/4885ALOX15 1853/4885
US-12084472-B2 Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists GPR119, GIPR, GLP1R CYP1A2 1241/4885ALDH1A1 4357/4885ALOX15 1853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.